Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function.

Escobar-Cabrera, Eric; Lario, Paula; Baardsnes, Jason; Schrag, Joseph; Durocher, Yves; Dixit, Surjit.

Afiliação

Escobar-Cabrera E; Zymeworks Inc., 540-1385 West 8th Ave, Vancouver, BC V6H 3V9, Canada. eescobar@zymeworks.com.
Lario P; Zymeworks Inc., 540-1385 West 8th Ave, Vancouver, BC V6H 3V9, Canada. plario@gmail.com.
Baardsnes J; Human Health Therapeutics, National Research Council Canada, 6100 Royalmount Ave, Montreal, QC H4P 2R2, Canada. Jason.Baardsnes@cnrc-nrc.gc.ca.
Schrag J; Human Health Therapeutics, National Research Council Canada, 6100 Royalmount Ave, Montreal, QC H4P 2R2, Canada. Joe.Schrag@cnrc-nrc.gc.ca.
Durocher Y; Human Health Therapeutics, National Research Council Canada, 6100 Royalmount Ave, Montreal, QC H4P 2R2, Canada. Yves.Durocher@cnrc-nrc.gc.ca.
Dixit S; Zymeworks Inc., 540-1385 West 8th Ave, Vancouver, BC V6H 3V9, Canada. sdixit@zymeworks.com.

Antibodies (Basel) ; 6(2)2017 May 16.

Article em En | MEDLINE | ID: mdl-31548523